Validation of DaTscan for Detection of Parkinson Disease Related Disorders
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This investigator initiated trial is designed to measure the accuracy of diagnosis of
Parkinson disease through the use of DaTscan. Currently, DaTscan is FDA approved to measure
dopamine transporter densities in human tissue. This measurement can assist in distinguishing
between Essential Tremor and Parkinsonian Syndromes (idiopathic Parkinson disease,
Progressive Supranuclear Palsy, Multi Systems Atrophy, etc). This study will compare both
clinical diagnosis of symptoms and the results of the scan to the pathological diagnosis
received at time of death. Patients will be registered in the Parkinson Research Institute's
brain donation program, receive a clinical diagnosis of Parkinson disease, have their brain
scanned using DaTscan, and donate their tissue for research and autopsy purposes. The
hypothesis of the study is that DaTscan will diagnosis Idiopathic Parkinson Disease as
accurately as a clinician.
Details
Lead Sponsor:
Wisconsin Institute for Neurologic and Sleep Disorders S.C.
Collaborators:
GE Healthcare Medical College of Wisconsin Wisconsin Parkinson Association